Topics

Aimmune's peanut allergy therapy recommended for approval by FDA committee

06:15 EDT 16 Sep 2019 | Pharmafile

The FDA’s Allergenic Products Advisory Committee (APAC) has recommended the use of Aimmune Therapeutics’ AR101, also known by its proposed brand name of Palforzia, in the treatment of peanut allergy among children and teens.

read more

Original Article: Aimmune's peanut allergy therapy recommended for approval by FDA committee

NEXT ARTICLE

More From BioPortfolio on "Aimmune's peanut allergy therapy recommended for approval by FDA committee"

Quick Search

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...